AIPM

Analysis of protein misfolding as a pathogenetic mechanism in autoinflammatory diseases

Coordinatore	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN    more  Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 contact info Titolo: Prof. Nome: Ania C. Cognome: Muntau Email: send email Telefono: +49 89 51602746 Fax: +49 89 51607952
Nazionalità Coordinatore	Germany [DE]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2010-RG
Funding Scheme	MC-IRG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-04-01   -   2015-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN  Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 contact info Titolo: Prof. Nome: Ania C. Cognome: Muntau Email: send email Telefono: +49 89 51602746 Fax: +49 89 51607952	DE (MUENCHEN)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Autoinflammatory diseases (AID) are an emerging group of mainly inherited disorders that lead to an innate immune dysregulation of cytokines. The common features are recurrent episodes of inflammation with fever. Systemic amyloidosis is the primary long-term morbidity, while treatment options are scarce. Thus, AID are associated with chronic disability and a significant impact on the health care system. Current data suggest protein misfolding with loss-of-function as a missense-induced principle in three monogenetic AID: tumor necrosis factor receptor-1 associated periodic syndrome, hyperimmunoglobulinemia D with periodic fever syndrome, and familial Mediterranean fever. The objective of this project is therefore to systematically elucidate the molecular mechanisms underlying these AID with the ultimate goal to develop targeted therapeutic strategies. A high-end technological platform will be used to analyze conformation, stability and function of the three mutant proteins TNFRSF1A, mevalonate kinase and pyrin. Analyses will be supplemented by the investigation of the effect of compound heterozygosity and digenity on protein misfolding. Protein-protein interaction (PPI) partners will be analyzed by the automated bioluminescence resonance energy transfer (BRET) technology for detection of PPI in living cells, thus allowing for an in-depth functional understanding of the target proteins. A hypothesis driven approach will be established to identify candidate compounds with potential protein-stabilizing properties followed by experimental validation of the chaperone effect. This innovative, translational approach sets the ground for future targeted therapies in AID. The project also will help to reintegrate a well-recognized physician-scientist with substantial clinical and scientific expertise in AID in Germany, thereby significantly increasing European excellence, while simultaneously supporting a lasting co-operation with the United States.'